LB Pharmaceuticals Inc LBRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 32.26M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 74.79
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 27
- Website
- https://www.lbpharma.us
Valuation
|
Metric
|
LBRX
|
|---|---|
Price/Earnings (Normalized) | 74.79 |
Price/Book Value | 3.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
LBRX
Financial Strength
|
Metric
|
LBRX
|
|---|---|
Quick Ratio | 13.91 |
Current Ratio | 15.08 |
Interest Coverage | — |
Quick Ratio
LBRX
Profitability
|
Metric
|
LBRX
|
|---|---|
Return on Assets (Normalized) | −27.46% |
Return on Equity (Normalized) | −31.73% |
Return on Invested Capital (Normalized) | −34.20% |
Return on Assets
LBRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|><Hcfky | LOCK|tsC$@ | $129B | |||
| Moderna Inc
MRNA
| LOCK|nDSxfn | LOCK|NK | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|zgY>x^ | LOCK|^@F< | $77B | |||
| argenx SE ADR
ARGX
| LOCK|w>m$D$d | LOCK|vH | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|g^&Vr?F | LOCK|T>& | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kSPm#B | LOCK|K&&!B | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@%mfJ^rp | LOCK|hnv!W | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|%db#rv& | LOCK|gk | $24B | |||
| Incyte Corp
INCY
| LOCK|&dSWnf | LOCK|@NF | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|K%%#T?L | LOCK|D> | $14B |
United States